phenotype of CAKUT.
The second is abnormalities in the genes responsible for the development of the kidney (Woolf, 2004; Merkel et al., 2007; Sanna-Cherchi et al., 2007) . Table 1 shows typical genes causing perturbation of kidney development which have been demonstrated using the targeting animal models. The critical molecules for the nephrogenesis include transcription factors, such as PAX2, WT1, SALL1 etc. and growth/survival factors and adhesion molecules.
The third factor is the substances, such as drugs and environmental compounds, which are transferred from the mother to the fetus through placental circulation, and will affect the fetal kidney. As described above, there are many critical molecules responsible for the development of the kidney, and perturbation of the function of those molecules seriously affect fetal kidney. The most well known substances are those possessing inhibitory effects on the rennin-angiotensin-aldosterone system.
Role of the renin-angiotensin-aldosterone system in renal development
The renin-angiotensin-aldosterone system, RAS system, plays the central role in the regulation of the cardi--tion to these physiological roles, RAS system has other biologic effects, such as cellular proliferation. Angiotensin II (ATII) promotes cellular growth via angiotensin II type 1 receptor (AT1 receptor). This function of ATII is essential for the development of the fetal kidney, especially in latter fetal life. Several gene targeted animal models, such as angiotensinogen (Kihara et al., 1998) and AT1 receptor knock-out (KO) mouse (Tsuchida et al., 1998) have been demonstrated to cause renal malformations. As shown in Fig. 2 , angiotensinogen KO mice showed a markedly atrophic papilla and dilated pelvis due to polyuria (Kihara et al., 1998) . The same phenotype is observed in AT1 function of the RAS system in the fetal kidney is essential for its normal development.
In rodents, neonatal kidney is morphologically and Table 1 . Abbreviations: c, comma-shaped body; g, glomerulus; m, mesenchymal; mc, mesenchymal condensate; s, S-shaped body;
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functionally immature, and its developmental state just corresponds to that of third trimester of the human kidney. When administered to neonatal rats, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) induce severe renal histological abnormalities, including papillary atrophy, tubulointerstiimpaired urinary concentrating capability (Guron et al., 1999; Chen et al. - tion rate (GFR) decreased probably due to the reduction in the number of glomeruli and wall thickening of cortical arterioles (Woods and Rasch, 1998) . Lasatiene et al. (2004) reported that the expression level of Na + -K + -2Cl -cotransporters in the thick ascending limb of Henle (TAL) was decreased in rats after the administration of losartan, an angiotensin II type 1 receptor blocker . These morphological and functional changes should cause impaired reabsorption of Na + and Cl -at TAL, resulting in the failure of osmotic gradient formation in the medulla, and consequently, in the impairment of the urinary concentrating capability.
ACEI/ARB fetopathy

Effect of inhibition of RAS system on fetal kidney
In the human, administration of ACEIs or ARBs to pregnant women causes severe oligohydramnion, neonafetal hypotension in the child, namely ACEI/ARB fetopathy. Most of the infants with ACEI/ARB fetopathy, progress to death or end-stage renal failure (ESRF) due to severely impaired renal function and hypoplastic lung due to oligohydramnion (Guignard and Gouyon, 1988; Pryde et al., 1993; Shotan et al., 1994; Schaefer, 2003) . Taken together, it is apparent that RAS system inhibition severely impairs morphology and function of the kidney, which is often fatal.
RESULTS AND DISCUSSION
Long term prognosis of ACEI/ARB fetopathy: renal outcomes of two ARB fetopathy patients
Since very few infants with ACEI/ARB fetopathy survive, the information on long-term outcome of ACEI/ ARB fetopathy are very limited (Guignard and Gouyon, 1988; Pryde et al., 1993; Shotan et al., 1994; Schaefer, 2003) . We experienced two children with ARB fetopathy who recovered from severe neonatal fetopathy. The following are the evaluation of their renal functions (Miura et al., 2009) .
Candesartan, an ARB, was administered to the mothers of the two patients during their pregnancy. Both patients were critically ill just after birth, and their clinical symptoms include severe renal failure, hypotension and respi--ical characteristics are compatible with the diagnosis of ARB fetopathy. Both of the patients received intensive care including mechanical ventilation, infusion of inotropic agents and dialysis.
After recovery from acute renal failure and respiratory failure, both patients developed polyuria and polydipsia, and showed marked growth retardation. The renal functions of the two patients at 6 and 2 years were as follows:
were mildly impaired.
2. Water restriction test revealed maximum urine osmolalities of 135 and 378 mOsm/kg in each patient, respectively, with no or little response to the injection of arginine vasopressin (AVP). Serum AVP, and urine cyclic AMP levels increased in response to water restriction in Fig. 2 . The renal morphogenetic abnormalities observed in angiotensinogen KO mice. (from Kihara et al., 1998, with permission) In angiotensinogen KO mice, a remarkably atrophic renal papilla (arrowhead), and marked dilation of pelvis (arrow) are noted.
Agt -/-mice Agt+/+ mice both patients, suggesting that the function of V2 receptor and subsequent signaling pathway is mostly intact.
3. The levels of serum endogenous AVP in both patients were markedly increased, before the injection of AVP and the urine osmolality again showed a negligible response to elevated urine-cAMP (from 135 to 168 mOsm/kg), the urinary concentrating defect should be mainly of renal origin.
4. Compared with the severe impairment of distal nephron segments, there were no significant dysfunctions in proximal tubule. Fractional excretion of uric acid (FEUA), transtubular reabsorption rate of phosphate (%TRP) were within normal ranges. Glucosuria, proteinuria, and aminoaciduria were not detected in both patients.
5. The plasma renin activity and aldosterone level were high in both patients, indicating that these patients are relatively hypovolemic status in their baseline condition.
These results suggest that remarkable salt-losing nephrogenic diabetes insipidus (NDI) due to impairment of formation of osmotic gradient in renal medulla is the central mechanism underlying in these patients. The predicted pathophysiology of these two patients is depicted in Fig. 3 .
The development and differentiation of renal progenitor cell is determined by interaction between ureteric bud and metanephric mesenchymal cells and expression of such molecules responsible for the development of the kidney are transcriptional factors, but there are also other critical genes, including those related to the RAS system. RAS system plays the central role in the homeostasis of the RAS system also contributes to the development and maturation of the renal systems essential for the retention of Na.
In conclusion, administration of ARBs to pregnant women could cause salt-losing polyuria with marked impairment of urinary concentrating ability unresponsive to AVP and reduction in GFR in the child. Even if -ing the neonatal period, they will suffer from salt-losing NDI, and thus, fail to thrive. This result emphasizes In the patients with ARB fetopathy, blunted action of ATII on fetal kidney fails to develop formation of osmotic gradient in renal medulla, which impairs the concentrating capability of the kidney. Reduced function of Na transport in TAL appears to enhance the Na loosing, which augment diuresis. Signal transduction via V2 receptor seems to be mostly preserved. Abbreviations; V2R, V2 receptor, ADH; anti-diuretic hormone, CD; collecting duct cell.
Normal
Signaling pathway via activated V2 receptor by AVP binding is presumed to be mostly normal 
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the importance of alerting obstetricians to the potential risks of ACEI/ARB administration to pregnant women. ACEIs/ARBs must not be administered to pregnant women throughout gestation.
